Enterprise Value
175.2M
Cash
612.8M
Avg Qtr Burn
-41.98M
Short % of Float
12.04%
Insider Ownership
15.72%
Institutional Own.
68.19%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LYL845 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
LYL797 Details Solid tumor/s, Cancer | Phase 1 Data readout |